Millennium Management
BCYC

Millennium Management’s Bicycle Therapeutics BCYC Stock Holding History

Millennium Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
553,967
+269,981
+95% +$1.24M ﹤0.01% 3691
2026
Q1 		$1.32M Sell
283,986
-42,640
-13% -$244K ﹤0.01% 4176
2025
Q4 		$2.31M Sell
326,626
-728,120
-69% -$5.37M ﹤0.01% 3813
2025
Q3 		$8.16M Sell
1,054,746
-388,873
-27% -$2.94M ﹤0.01% 2597
2025
Q2 		$10M Buy
1,443,619
+990,191
+218% +$7.89M ﹤0.01% 2248
2025
Q1 		$3.85M Buy
453,428
+276,671
+157% +$3.26M ﹤0.01% 3122
2024
Q4 		$2.47M Buy
+176,757
New +$3.79M ﹤0.01% 3454
2024
Q3 		– Sell
-37,507
Closed -$759K – 6093
2024
Q2 		$759K Buy
+37,507
New +$847K ﹤0.01% 4311
2024
Q1 		– Sell
-249,135
Closed -$4.5M – 6178
2023
Q4 		$4.5M Sell
249,135
-65,958
-21% -$1.09M ﹤0.01% 2879
2023
Q3 		$6.33M Buy
315,093
+236,334
+300% +$5.4M ﹤0.01% 2482
2023
Q2 		$2.01M Buy
78,759
+61,923
+368% +$1.44M ﹤0.01% 3480
2023
Q1 		$358K Sell
16,836
-151,887
-90% -$3.81M ﹤0.01% 4799
2022
Q4 		$4.99M Buy
168,723
+25,677
+18% +$689K ﹤0.01% 2811
2022
Q3 		$3.33M Sell
143,046
-190,655
-57% -$4.54M ﹤0.01% 3282
2022
Q2 		$5.6M Buy
333,701
+170,334
+104% +$3.59M ﹤0.01% 2681
2022
Q1 		$7.17M Buy
163,367
+10,635
+7% +$497K ﹤0.01% 2535
2021
Q4 		$9.3M Buy
+152,732
New +$8.43M ﹤0.01% 2216
2021
Q3 		– Sell
-20,363
Closed -$618K – 6777
2021
Q2 		$618K Buy
+20,363
New +$615K ﹤0.01% 5113
2021
Q1 		– Sell
-14,442
Closed -$259K – 5910
2020
Q4 		$259K Buy
14,442
+961
+7% +$18.6K ﹤0.01% 4652
2020
Q3 		$257K Sell
13,481
-4,833
-26% -$85.4K ﹤0.01% 3933
2020
Q2 		$284K Buy
18,314
+3,073
+20% +$47.2K ﹤0.01% 3685
2020
Q1 		$228K Sell
15,241
-5,949
-28% -$75.8K ﹤0.01% 3321
2019
Q4 		$200K Sell
21,190
-13,579
-39% -$123K ﹤0.01% 3886
2019
Q3 		$396K Sell
34,769
-18,591
-35% -$160K ﹤0.01% 3404
2019
Q2 		$537K Buy
+53,360
New +$643K ﹤0.01% 3177

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Millennium Management's BCYC Position: Q2 2026 in Review

Millennium Management increased its Bicycle Therapeutics (BCYC) stake by 95% in Q2 2026, buying an estimated $1.24M and bringing the position to 553,967 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

Millennium Management first reported a position in BCYC in Q2 2019 and has held it in 25 quarters since. The position peaked at $10M in Q2 2025. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Millennium Management held 553,967 shares of Bicycle Therapeutics worth $2.35M as of Q2 2026.
  • Millennium Management bought 269,981 Bicycle Therapeutics shares in Q2 2026, an estimated $1.24M.
  • Bicycle Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #3691 holding.
  • Millennium Management first reported a position in Bicycle Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Millennium Management's Bicycle Therapeutics position peaked at $10M in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.